Summary
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
History
Founded in 2005 by a group of dedicated London-based healthcare professionals, Harrow Health is a not-for-profit organisation that provides vital health and social care services to individuals and local communities. Our team works to provide innovative, effective and affordable health services that are tailored to the individual, to ensure that all members of the community have access to the best possible care.
Mission
We strive to provide our patients and their families with the best quality of care and compassion to meet the physical, emotional and spiritual needs of all persons. We aim to ensure excellence in our services and to value the individual with dignity, respect and understanding.
Vision
We aspire to be a world-leading provider of holistic and minimally-invasive health care, leading the way in community well-being and improving quality of life through innovative and accessible health care.
Key Team
Mr. John P. Saharek MBA (Chief Commercial Officer)
Mr. David Moufarrège (VP of Technology)
Jamie Webb (Director of Communications & Investor Relations)
Dr. Dennis E Saadeh Pharm.D. (Chief of Formulation Strategy)
Dr. Larry M. Dillaha M.D. (Chief Medical Officer)
Mr. Andrew Livingston (Chief Innovation Officer)
Ms. Kim Barratt (Chief Talent Officer)
Recognition and Awards
Harrow Health has been awarded the Queen's Award for Voluntary Service for our commitment to outstanding patient care and quality healthcare services. We’ve also been recognised by the National Institute for Health and Care Excellence for our work in treating older people in the community and reducing unnecessary hospital admissions.
References
United States 